Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Graveobioside A in preparation of drugs or healthcare food for preventing hyperuricemia and gout

A technology for hyperuricemia, health food, applied in the fields of natural medicinal chemistry and medicine

Inactive Publication Date: 2016-05-11
KUNMING INST OF BOTANY - CHINESE ACAD OF SCI +1
View PDF1 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Patent ZL200710062800.6 extracts the celery seed extract through petroleum ether and ethyl acetate several times to obtain the celery seed ethyl acetate extract, which contains 6 coumarins and 12 flavonoids, Among them, the flavonoids include GraveobiosideA, which only has xanthine oxidase inhibitory activity on coyilidin, luteolin, and apigenin in 18 compounds. The effect of coyilidin on hyperuricemia models on mice has not yet been tested. GraveobiosideA conducts anti-gout-related pharmacological activity experiments

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Graveobioside A in preparation of drugs or healthcare food for preventing hyperuricemia and gout
  • Application of Graveobioside A in preparation of drugs or healthcare food for preventing hyperuricemia and gout
  • Application of Graveobioside A in preparation of drugs or healthcare food for preventing hyperuricemia and gout

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Preparation method of GraveobiosideA:

[0034] Celery dry seeds 10kg, with 8-15 times the amount of 30-70% (V / V) ethanol percolation extraction or heating extraction 2-4 times, each time for 0.5-2 hours, the extract is concentrated under reduced pressure to nearly no ethanol, and then concentrated Extract the liquid with 1 to 3 times of ethyl acetate for 1 to 3 times, separate the ethyl acetate and recover the ethyl acetate, pass the water layer through the D101 macroporous adsorption resin, elute with water first, then elute with 50% ethanol, Collect 0% ethanol eluate, concentrate, concentrate on silica gel column chromatography, use chloroform:methanol (90:10-0:100) gradient elution, collect eluate in sections, follow up with thin layer chromatography, and combine GraveobiosideA The fractions were concentrated, and the concentrate was purified by SephadexLH-20 gel chromatography, eluted with methanol, the eluate was collected, concentrated and dried under reduced pres...

Embodiment 2

[0046] Effect of GraveobiosideA on hyperuricemia induced by oxonic acid potassium salt in mice:

[0047] The three dosage groups of Graveobioside A in Example 1 are 20, 10, and 5 mg / kg respectively, and are prepared into solutions with concentrations of 1, 0.5, and 0.25 mg / mL with pure water; allopurinol tablets are prepared with 2 mg / mL concentration with pure water suspension.

[0048] Seventy-two male ICR mice of 21-24 g were randomly divided into 6 groups according to body weight: normal control group; model control group; positive control allopurinol tablet 40 mg / kg group; Graveobioside A20, 10, 5 mg / kg group. Except for the positive control allopurinol tablet, which was intragastrically administered once on the day of the experiment, the animals in the other groups were intragastrically administered once a day according to the dose, for 3 consecutive days. On the 2nd day, the mice were fasted overnight (12h), and in the morning of the next day, except the normal control...

Embodiment 3

[0057] Effect of GraveobiosideA on carrageenan-induced paw swelling in mice:

[0058] The three dosage groups of Graveobioside A in Example 1 were 200, 100, and 50 mg / kg respectively, and were prepared into solutions with concentrations of 1, 0.5, and 0.25 mg / mL with pure water; mg / mL suspension.

[0059] Male ICR mice of 19-21 g were selected and randomly divided into 5 groups according to body weight: control group; positive control groups of indomethacin tablet 10 mg / kg, Graveobioside A20, 10, 5 mg / kg, 12 in each group. Except for the indomethacin tablet which was administered by intragastric administration only once on the day of the experiment, the animals in the other groups were intragastrically administered once a day according to the dose for 3 consecutive days, and the control group was given 20mL / kg.bw of pure water. 30 minutes after the last administration, 0.05 mL / foot of 1% carrageenan was subcutaneously injected into the right hind foot of the mice in each grou...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of Graveobioside A in the preparation of drugs or healthcare food for preventing hyperuricemia and gout. The invention also provides a drug or healthcare food for treating hyperuricemia and gout. Graveobioside A is the active component and is mixed with a proper amount of pharmaceutical carrier or excipient to prepare preparations. Graveobioside A can prominently reduce uric acid in serum of an oteracil potassium caused hyperuricemia model mouse, reduces the activity of xanthine oxidase at different levels, and prominently inhibit the arthritis of mouse. Graveobioside A can treat and prevent hyperuricemia and gout and can be used to prepare drugs or healthcare food for preventing hyperuricemia and gout.

Description

technical field [0001] The invention belongs to the technical fields of natural medicinal chemistry and medicine, and in particular relates to the application of Graveobioside A in the preparation of anti-hyperuricemia and anti-gout drugs. Background technique [0002] Gout is a disease caused by the chronic deposition of fine needle-shaped urate. The biochemical marker of gout is hyperuricemia. Its clinical manifestations are gouty arthritis and joint deformity caused by high urate crystals, and symptoms such as redness, swelling, heat, and pain appear in the whole body. Gout is generally divided into asymptomatic stage, acute arthritis stage, intermittent stage and chronic stage. In the arthritic phase, gout often presents only intermittent episodes of acute arthritis in the early stages. Mainly single joint involvement, joint swelling and pain usually lasts for 7-10 days, can be relieved spontaneously or by medication, without any symptoms during the intermittent period....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048C07H17/07C07H1/08A61K36/23A61P19/06
CPCA61K31/7048A61K9/0095A61K9/08A61K36/23C07H1/08C07H17/07
Inventor 陈纪军杨通华黄晓燕马云保张雪梅沈勇耿长安卢承杰
Owner KUNMING INST OF BOTANY - CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com